Pharmacists play a critical role in detecting and reporting adverse events from generic medications. Learn why their reports matter, how to report correctly, and how under-reporting puts patients at risk.
Triptans are effective for migraines but come with serious interactions and limitations. Learn when they work, when they fail, and which drugs to avoid mixing with them.
Antiviral medications like Paxlovid, Tamiflu, and hepatitis C cures help treat viral infections by stopping viral replication. Learn how they work, which ones are most effective, and why timing and access matter.
MAO inhibitors can save lives for treatment-resistant depression-but eating the wrong foods can cause a dangerous blood pressure spike. Learn which foods to avoid, how newer MAOIs reduce risks, and what to do if you accidentally eat tyramine.
Learn when to use OTC diarrhea treatments like Imodium and Pepto-Bismol-and when to skip them and see a doctor. Safe dosing, red flags, hydration tips, and what to avoid.
Prescribers remain cautious about substituting generic drugs for narrow therapeutic index medications due to risks of instability and adverse effects. Despite FDA assurances, doctors prioritize patient safety through careful monitoring and controlled switching.
Generic drugs save the U.S. healthcare system nearly $500 billion annually by providing the same effectiveness as brand-name medications at a fraction of the cost. Discover how generics and biosimilars are reshaping drug pricing and what you can do to save money.
Pharmacists play a critical role in spotting and reporting generic drug problems like therapeutic inequivalence and manufacturing issues. Though not legally required in most states, reporting adverse events to the FDA through MedWatch is a professional obligation that protects patient safety.
Despite being just as safe and effective as brand-name drugs, generics face widespread public mistrust fueled by misleading media coverage. Learn how news stories shape perceptions - and what can be done to restore confidence.
The Hatch-Waxman Act of 1984 created the modern system for generic drugs in the U.S., balancing innovation incentives with affordable access. It cut approval costs by 90%, boosted generic use to 90% of prescriptions, and sparked ongoing debates over drug pricing.